Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Cristofanilli on Survival Findings From the PALOMA-3 Trial

October 20th 2018

Massimo Cristofanilli, MD, professor of medicine (hematology and oncology), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses survival findings from the PALOMA-3 trial in hormone receptor-positive, HER2-negative breast cancer.

Atezolizumab Combo Improves PFS in Frontline Metastatic TNBC

October 20th 2018

The addition of atezolizumab to nab-paclitaxel reduced the risk of progression or death by 38% compared with nab-paclitaxel alone in patients with PD-L1–positive metastatic triple-negative breast cancer.

Dr. Gradishar on Personalized Treatment in Breast Cancer

October 17th 2018

William J. Gradishar, MD, chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the rise of personalized treatment in breast cancer.

Dr. King on Surgical Approaches in Breast Cancer

October 17th 2018

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses surgical approaches in breast cancer.

Dr. Yardley on the FDA Approval of Talazoparib in Breast Cancer

October 16th 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the FDA approval of talazoparib (Talzenna) for the treatment of patients with germline BRCA mutation–positive, HER2-negative locally advanced or metastatic breast cancer

FDA Approves Talazoparib for BRCA-Mutated, HER2-Negative Breast Cancer

October 16th 2018

The FDA has approved talazoparib (Talzenna) for patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer.

Dr. Cristofanilli Discusses Roles of a Multidisciplinary Team in Breast Cancer

October 14th 2018

Massimo Cristofanilli, MD, discusses a session at the 20th Annual Lynn Sage Breast Cancer Symposium on the roles of a multidisciplinary team.

Dr. Sledge on Genomic Sequencing in Patients With Breast Cancer

October 14th 2018

George Sledge, Jr., MD, discusses the benefit to the cost of genomic sequencing decreasing overtime.

Molecular Profiling in Metastatic Breast Cancer: Not Yet Standard of Care, But May Be in Near Future

October 14th 2018

As the cost of sequencing continues to fall, genomic testing will likely become widespread in all types of metastatic cancer, including breast cancer.

Gradishar Addresses 20 Years of Breast Cancer Advancements

October 14th 2018

William J. Gradishar, MD, discusses how far the breast cancer field has advanced over the last 20 years and the data he is anticipating to read out in the future.

Predictive Value Examined Among Genomic Tests for Breast Cancer

October 14th 2018

Multiple gene signature assays have been developed that supply prognostic information for decisions on adjuvant chemotherapy and whether therapy should be of extended duration.

Progress Emerging With Optimal Adjuvant Therapy in Young Women With Breast Cancer

October 14th 2018

Determining the optimal adjuvant therapy in young women with breast cancer remains challenging, but some clarity is beginning to emerge.

Dr. Ruddy on the Importance of Genetic Testing in Breast Cancer

October 13th 2018

Kathryn Ruddy, MD, discusses how genetic testing could impact treatment of patients with breast cancer.

Challenges Remain in Treating Patients With Phyllodes Breast Tumors

October 13th 2018

Andrea V. Barrio, MD, discusses the challenges with phyllodes tumors of the breast and how to manage this disease moving forward.

Dr. Mittendorf Discusses Rationale for Updating the AJCC Staging System

October 13th 2018

Elizabeth Mittendorf, MD, PhD, discusses the rationale for updating the AJCC staging system in patients with breast cancer. This system was originally developed in the 1970s but is still used today.

Conventional View May Not Apply for All Triple-Negative Breast Cancers

October 13th 2018

All triple-negative breast cancers are not created equal, and clinicians should consider their inherent heterogeneity during diagnosis and treatment planning.

Expert Highlights Management of Locoregional Recurrence in Breast Cancer

October 13th 2018

Monica Morrow, MD, addresses how she treats patients with breast cancer who have locoregional recurrence and how therapeutic approaches have evolved over recent years.

Dr. McLaughlin on Lymphedema in Breast Cancer

October 12th 2018

Sara McLaughlin, MD, professor of Surgery, Mayo Clinic, discusses the frequency that lymphedema appears in patients with breast cancer and addresses the complications in identifying this after her presentation at the Lynn Sage Breast Cancer Symposium.

Emerging Role of TILs in Breast Cancer Leads to Expanding Pathology Practices

October 12th 2018

Just as immunotherapies are transforming clinical practice for oncologists, these new therapies are also changing the practice of pathology and offering new ways for oncologists and pathologists to collaborate and improve patient care.

Dr. Blanco on the Role of Pathology in Treatment of Breast Cancer

October 12th 2018

Luis Z. Blanco Jr., MD, assistant professor of Pathology, Northwestern University, discusses the role a pathologist plays in the treatment of a patient with breast cancer during a presentation at the Lynn Sage Breast Cancer Symposium.